The extent of injection site infection in injecting drug users: Findings from a national surveillance study

Epidemiology and Infection

Volumn 138, Issue 10, 2010, Pages 1510-1518

  Hope, V D ^a,b   Marongiu, A ^a   Parry, J V ^a,b   Ncube, F ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Injecting drug users (IDUs); skin infections; surveillance

Indexed keywords

CENTRAL STIMULANT AGENT; OPIATE;

ADULT; ARTICLE; DISEASE SURVEILLANCE; FEMALE; FILTER; HEALTH SURVEY; HOMELESSNESS; HUMAN; INFECTION PREVENTION; INJECTION SITE ABSCESS; INJECTION SITE INFECTION; INJECTION SITE SWELLING; INTRAVENOUS DRUG ABUSE; IRELAND; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SELF REPORT; SEX DIFFERENCE; TREND STUDY; UNITED KINGDOM; ADOLESCENT; CROSS-SECTIONAL STUDY; DRUG USE; INJECTION; MIDDLE AGED; PATHOLOGY; SUBSTANCE ABUSE; WOUND INFECTION;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; DRUG USERS; ENGLAND; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NORTHERN IRELAND; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; WALES; WOUND INFECTION; YOUNG ADULT;

EID: 77956415993     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268810000324     Document Type: Article

References (40)

1. Cherubin C, Sapira J. The medical complications of drug addiction and the medical assessment of the intravenous drug user. Annals of Internal Medicine 1993;119:1017-1028.
2. Del Guidice P. Cutaneous complication of intravenous drug abuse. British Journal of Dermatology 2004;150:1-10.
3. Lloyd-Smith E, et al. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health 2008;8:405.
4. Salmon AM, et al. Injecting-related injury and disease among clients of a supervised injecting facility. Drug & Alcohol Dependence 2009;101:132-136.
5. Takahasi T, et al. Type and location of injection drug use-related soft tissue infections predict hospitalization. Journal of Urban Health 2003;80:127-136.
6. Biswanger I, et al. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Fransisco. Clinical Infectious Diseases 2000;30:579-581.
7. Lloyd-Smith E, et al. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal 2005;2:24.
8. Hope V, et al. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infectious Diseases 2008;8:120.
9. Kerr T, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. Journal of Public Health (Oxford) 2005;27:62-66.
10. Palepu A, et al. Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal 2001;165:415-420.
11. Murphy E, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clinical Infectious Diseases 2001;33:35-40.
12. Vlahov D, et al. Bacterial infections and skin cleaning prior to infection among intreavenous drug users. Public Health Reports 1992;107:595-598.
13. Dwyer R, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug & Alcohol Dependence 2009;100:9-16.
14. Topp L, et al. Prevalence and predictors of injectingrelated injury and disease among clients of Australia's needle and syringe programs. Australia & New Zealand Journal of Public Health 2008;32:34-37.
15. Spijkerman I, van Ameijden EJ, Mientjes G. Human immunodeficiency virus and other risk factors for skin abscesses and endocarditis among injection drug users. Journal of Clinical Epidemiology 1996;49:1149-1154.
16. Darke S, Ross J, Kaye S. Physical injecting sites among injecting drug users in Sydney, Australia. Drug & Alcohol Dependence 2001;62:77-82.
17. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, and the UASSG. Shooting Up: Infections Among Injecting Drug Users in the United Kingdom 2007. London: Health Protection Agency, October, 2008.
18. Lamagni TL, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerging Infectious Diseases 2008;14:202-209.
19. Irish C, et al. Skin and soft tissue infections and vascular disease among drug users, England [Letter]. Emerging Infectious Diseases 2007;13(October).
20. Jones JA, et al. An outbreak of serious illness and death among injecting drug users in England and Wales during 2000. Journal of Medical Microbiology, 2002;51:978-984.
21. Beeching, NJ, Crowcroft NS. Tetanus in injecting drug users. The latest Clostridium infection to threaten injectors in Britain. British Medical Journal 2005;330:208-209.
22. Akbulut D, et al. Outbreak report: Wound botulism in injectors of illicit drugs: upsurge in cases in England during 2004. Eurosurveillance Monthly 2005;10(September).
23. Kearns AM, et al. An unusual clone of MRSA causing infection in injecting drug users. Journal of Infection 2004;49:49-50.
24. Morrison A, Elliott L, Gruer L. Injecting-related harm and treatment seeking behaviour among injecting drug users. Addiction 1997;92:1349-1352.
25. Noone A, et al. HIV infection in injecting drug users attending centres in England and Wales, 1990-1991. AIDS 1993;7:1501-1507.
26. Gordon L, et al. The Economic and Social Costs of Class A Drug use in England and Wales, 2003/04. In: Singleton N, Murray R, Tinsley L, eds. Measuring different aspects of problem drug use: methodological developments. London, Home Office, 2006. Home Office Online Report, 16/06.
27. Ciccarone D, et al. Soft tissue infections among injection drug users-San Francisco, California, 1996-2000. Morbidity & Mortality Weekly Reports: CDC Surveillance Summaries 2001;50:381-384.
28. French M, et al. Chronic illicit drug use, health services utilisation and the cost of medical care. Social Science & Medicine 2000;50:1703-1713.
29. van Beek I, Dwyer R, Malcom A. Cocaine injecting: the sharp end of drug related harm! Drug & Alcohol Review 2001;20(Harm Reduction Digest 14):333-342.
30. Harris H, Young D, Organ Jr. C. Care of injection drug users with soft tissue infections in San Fransisco, California. Archives of Surgery 2002;137:1217-1222.
31. Grau L, et al. Expanding harm reduction services through a wound and abscess clinic. American Journal of Public Health 2002;92:1915-1917.
32. Rhodes T, et al. Groin injecting in the context of crack cocaine and homelessness: From "risk boundary" to "acceptable risk"? International Journal of Drug Policy 2006;17:164-170.
33. Rhodes T, et al. Crack-heroin speedball injection and its implications for vein care: qualitative study. Addiction 2007;102:1782-1789.
34. Hope VD, Hickman M, Tilling K. Capturing crackcocaine use: Estimating the prevalence of Crackcocaine use in London using capture-recapture with covariates. Addiction 2005;100:1701-1708.
35. Van Den Berg C, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007;102:1454-1462.
36. Vickerman P, Hickman M, Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 2007;36:396-405.
37. Craine N, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection 2009;137:1255-1265.
38. NICE. Needle and syringe programmes: providing people who inject drugs with injecting equipment. National Institute for Health and Clinical Excellence, Public Health Guidance, PH18, February 2009 (http://guidance.nice.org.uk/PH18).
39. Harm Reduction Works. National Treatment Agency for Substance Use and Exchange Supplies. (www.harmreductionworks.org.uk/). Accessed 17 August 2009.
40. Hickman M, et al. Hepatitis C (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. Journal of Viral Hepatitis 2007;14:645-652.